Neuromyelitis OpticaSymptoms, Doctors, Treatments, Advances & More
Learn About Neuromyelitis Optica
Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.
No genes associated with neuromyelitis optica have been identified. However, a small percentage of people with this condition have a family member who is also affected, which indicates that there may be one or more genetic changes that increase susceptibility. It is thought that the inheritance of this condition is complex and that many environmental and genetic factors are involved in the development of the condition.
Neuromyelitis optica affects approximately 1 to 2 per 100,000 people worldwide. Women are affected by this condition more frequently than men.
Neuromyelitis optica is usually not inherited. Rarely, this condition is passed through generations in families, but the inheritance pattern is unknown.
Johns Hopkins Outpatient Center
Elias Sotirchos, M.D., specializes in the diagnosis, management and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents. Dr. Sotirchos earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his internship and neurology residency training at The Johns Hopkins Hospital. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National MS Society Sylvia Lawry Fellow. Dr. Sotirchos is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis. Dr. Sotirchos is board certified in American Board Of Psychiatry And Neurology.
Vanderbilt Medical Group- Teleneurology
. Dr. Bagnato is rated as a Distinguished provider by MediFind in the treatment of Neuromyelitis Optica. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Neuromyelitis Optica, Optic Neuritis, and Relapsing Multiple Sclerosis (RMS). Dr. Bagnato is board certified in .
Atrium Health Neurology Specialty Care
Donna Graves is a Neurologist practicing medicine in Charlotte, North Carolina. Dr. Graves is rated as an Advanced provider by MediFind in the treatment of Neuromyelitis Optica. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Neuromyelitis Optica, and Optic Neuritis. Dr. Graves is board certified in American Board Of Psychiatry And Neurology. Dr. Graves is currently accepting new patients.
Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
Summary: This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
Published Date: March 01, 2015
Published By: National Institutes of Health